metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALC...
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Acceso a texto completo
O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY
Visitas
290
Francisco Idalsoaga1, Luis Antonio Díaz1, Gustavo Ayares1, Jorge Arnold1, Winston Dunn2, Yanming Li2, Ashwani Singal3, Doug Simonetto4, María Ayala-Valverde5, Diego Perez4, Jaime Gomez5, Rodrigo Escarate5, Eduardo Fuentes-López6, Carolina A Ramirez7, Dalia Morales-Arraez8, Wei Zhang9, Steve Qian9, Joseph Ahn4, Seth Buryska4, Heer Mehta2..., Muhammad Waleed3, Horia Stefanescu10, Adelina Horhat10, Andreea Bumbu10, Bashar Attar11, Rohit Grawal12, Joaquín Cabezas13, Inés García-Carrera13, Berta Cuyàs14, Maria Poca14, German Soriano Pastor14, Shiv K Sarin15, Rakhi Maiwall15, Prasun K Jalal16, María Fátima Higuera-De La Tijera17, Anand Kulkarni18, Nagaraja Rao P18, Patricia Guerra Salazar19, Lubomir Skladaný20, Natália Bystrianska20, Veronica Prado21, Ana Clemente-Sanchez22, Diego Rincón22, Tehseen Haider23, Kristina R Chacko23, Gustavo A Romero24, Florencia D Pollarsky24, Juan Carlos Restrepo25, Luis G Toro26, Pamela Yaquich27, Manuel Mendizabal28, Maria Laura Garrido29, Sebastian Marciano30, Melisa Dirchwolf31, Victor Vargas32, Cesar Jimenez32, Guadalupe García-Tsao33, Guillermo Ortiz33, Juan G Abraldes34, Patrick Kamath4, Marco Arrese1, Vijay Shah4, Ramon Bataller8, Juan Pablo Arab1,35,36Ver más
1 Department of Gastroenterology, Medical School, Pontifical Catholic University of Chile, Santiago, Chile
2 Division of Gastroenterology and Hepatology, University of Kansas Medical Center, KS, USA
3 Division of Gastroenterology and Hepatology, Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA
4 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
5 Internal Medicine Service, El Pino Hospital, Santiago, Chile
6 Department of Health Sciences, Faculty of Medicine, Pontifical Catholic University of Chile, Santiago, Chile
7 Department of Anesthesiology, Las Condes Clinic, Santiago, Chile
8 Center for Liver Diseases, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, PA, USA
9 Division of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA
10 Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania
11 Division of Gastroenterology & Hepatology, Cook County Health and Hospital Systems, Chicago, Illinois, USA
12 Division of Gastroenterology and Hepatology, University of Illinois, Chicago, Illinois, USA
13 Gastroenterology and Hepatology Department. University Hospital Marques de Valdecilla. Santander. Spain; Research Institute Valdecilla (IDIVAL). Santander. Spain
14 Department of Gastroenterology, Hospital de La Santa Creu I Sant Pau, Ciberehd, Barcelona, Spain
15 Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India
16 Department of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, USA
17 Gastroenterology Service, General Hospital of México, National Autonomous University of México, México City, México
18 Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India
19 Gastroenterology Department, Gastroenterology Institute Bolivian-Japanese, La Paz, Bolivia
20 Division of Hepatology, Gastroenterology and Liver Transplantation, Department of Internal Medicine II, Slovak Medical University, F. D. Roosevelt University Hospital, Banska Bystrica, Slovak Republic
21 Hepatology, Centre Hospitalier de Luxembourg, Luxembourg
22 Liver Unit, Department of Digestive Diseases University General Hospital Gregorio Marañón Madrid, Spain; Ciberehd Biomedical Research Center in the Liver and Digestive Diseases Network Madrid, Spain
23 Division of Gastroenterology and Hepatology, Montefiore Medical Center, Bronx, NY, USA
24 Hepatology Section, Gastroenterology Hospital Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina
25 Hepatology Unit, Pablo Tobon Uribe Hospital, university of Antioquia, Medellín, Colombia
26 Hepatology and Liver Transplant Unit, Hospitals of San Vicente Fundación, Medellín-Rionegro, Antioquia, Colombia
27 gastroenterology Department, San Juan de Dios Hospital, Santiago, Chile
28 Hepatology and Liver Transplant Unit, Austral University Hospital, Pilar, Argentina
29 Central Hospital San Luis, San Luis, Argentina
30 Liver Unit, Buenos Aires Italian Hospital, Buenos Aires, Argentina
31 Liver Unit, Rosario Private Hospital, Rosario, Argentina
32 Liver Unit, Hospital Vall D'hebron, Universitat Autonoma Barcelona, Ciberehd, Barcelona, Spain
33 Section of Digestive Diseases, Yale University School of Medicine/VA-CT Healthcare System, New Haven/West Haven, USA
34 Division of Gastroenterology, Liver Unit, University of Alberta, Edmonton, Canada
35 Division of Gastroenterology, Department of Medicine, Schulich School of Medicine, Western University & London Health Sciences Centre, London, Ontario, Canada
36 Department of Epidemiology and Biostatistics, Schulich School of Medicine, Western University, London, Ontario, Canada
Ver más
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Tablas (1)
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

Alcohol-associated hepatitis (AH) is a severe entity associated with high mortality. Corticosteroids might be used in cases with severe disease and several dynamic models can predict mortality and response to corticosteroids in AH patients. However, there is no consensus on the best of them. This study aimed to evaluate dynamic models to predict response to corticosteroid treatment based on short-term mortality in patients with severe AH based on a worldwide cohort.

Materials and Methods

A retrospective cohort study of patients with severe AH (between 2009 – 2019). We included patients who received corticosteroid treatment and calculated the Lille model of day 4 (Lille-4), day 7 (Lille-7) (cut-off value ≥0.45), and the Trajectory of Serum Bilirubin (TSB)(cut-off value ≥0.8 of the ratio between bilirubin at admission and day 7) to predict mortality. We estimated up to 30-day survival using Kaplan-Meier curves, and we performed multivariable analyzes using Cox regression. Specifically, we constructed two models to compare Lille-4 vs. TSB and Lille-7 vs. TSB, adjusting by well-known clinical variables associated with higher mortality in AH (age, sex, and creatinine at admission).

Results

1,066 patients were included (30 centers, 10 countries), age 47.7 ± 10.9 years, 30% women. The MELD score on admission was 25 [21-30]. Responders were considered by Lille-4 49.1%, Lille-7 46.6%, and TSB 55.4%. In the first Cox regression, we observed that Lille-4 and TSB predicted 30-day mortality (HR 3.0, 95%CI: 1.7-5.1; p<0.0001, and HR 2.1, 95%CI: 1.3-3.5; p=0.005, respectively) (Table A). In the second Cox regression, Lille-7 also predicted 30-day mortality (HR 3.7, 95%CI: 2.1-6.7; p<0.0001) but not TSB (HR 1.5, 95% CI: 0.8-2.6; p=0.180) (Table B). Creatinine at admission was also statistically significant in both Cox-regressions.

Conclusions

Different dynamic models can determine the response to corticosteroids in patients with severe AH. However, Lille-7 and Lille-4 have the best performance. New models are needed for better prognostication in AH.

Texto completo

Table 1: Models to compare Lille-4 vs. TSB (Table A) and Lille-7 vs. TSB (Table B)

Table A
Variable  Hazard Ratio  P value  95 % Conf. Interval 
Age  0.999  0.933  0.98 - 1.01 
Gender  0.954  0.829  0.62 - 1.45 
Creatinine in Admission  1.195  0.00  1.08 - 1.31 
Lille- 7 Response  3.706  0.00  2.05 - 6.68 
TSB Response  1.476  0.180  0.83 - 2.60 
Table B
Variable  Hazard Ratio  P value  95 % Conf. Interval 
Age  0.999  0.948  0.98 - 1.01 
Gender  0.911  0.678  0.58 - 1.40 
Creatinine in Admission  1.193  0.001  1.07 - 1.31 
Lille- 4 Response  2.99  0.00  1.74 - 5.14 
TSB Response  2.08  0.005  1.25 - 3.45 

Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos